Wandercraft is carrying exoskeleton proof into humanoid factory work

Wandercraft announced $75 million in equity and debt on June 11, 2025 for its exoskeleton and humanoid programs. The company says Atalante X is used in more than 100 rehabilitation centers across four continents, and that 2,500 people with mobility disabilities have taken more than 14 million steps with its systems.

The funding covers Eve, Atalante X, and Calvin-40 without forcing them into one market. Wandercraft plans to move Eve toward personal exoskeleton commercialization, expand Atalante X clinical adoption, and develop Calvin-40 for industrial work.

Wandercraft said Renault Group took a minority stake and became the first commercial partner and customer for Calvin-40, bringing manufacturing expertise to help scale production. Calvin-40 was developed in 40 days using Wandercraft's robotics platform with NVIDIA Isaac technologies, including Isaac GR00T N1 and Jetson edge AI.

Wandercraft was founded in 2012 in France by Nicolas Simon, Alexandre Boulanger, Matthieu Masselin, and Jean-Louis Constanza after early bipedal-robotics work at Ecole Polytechnique. Its platform uses a proprietary neural network trained on billions of steps and refined through clinical use.

Atalante X has clinical deployments, while Calvin-40 is being developed with Renault under a customer agreement.

Have a robotics update Korthos should review? Send news, deployments, product releases, funding rounds, research, or media to [email protected] or reach out on X at @agkorthos.